Found: 8
Select item for more details and to access through your institution.
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 758, doi. 10.1111/dom.15340
- By:
- Publication type:
- Article
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2331, doi. 10.1111/dom.15112
- By:
- Publication type:
- Article
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2043, doi. 10.1111/dom.15065
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2038, doi. 10.1111/dom.15057
- By:
- Publication type:
- Article
A retrospective observational population‐based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m<sup>2</sup> in Ontario, Canada.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 4, p. 916, doi. 10.1111/dom.14294
- By:
- Publication type:
- Article
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 691, doi. 10.1111/dom.13573
- By:
- Publication type:
- Article
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
- Published in:
- Journal of the American Heart Association, 2024, v. 13, n. 3, p. 1, doi. 10.1161/JAHA.123.031586
- By:
- Publication type:
- Article
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
- Published in:
- Diabetes Care, 2024, v. 47, n. 3, p. 501, doi. 10.2337/dc23-1450
- By:
- Publication type:
- Article